ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

Merck & Co. and Daiichi Sankyo on Tuesday said one of the drug candidates in their multibillion-dollar collaboration has hit its main goal in a late-stage lung-cancer study. Merck and Daiichi ...

An antibody-drug conjugate developed by Daiichi Sankyo and Merck & Co. met the main goal of a Phase 3 lung cancer trial ... discovered the breast cancer ADC Enhertu — one of the most successful ...

Sept 17 (Reuters) - Daiichi Sankyo (4568.T), opens new tab and Merck ... met the main goal of extending the time some patients with a form of lung cancer lived without their disease progressing ...

Daiichi Sankyo has six ADCs in clinical development across multiple types of cancer, being developed utilizing its DXd ADC technology. It markets Enhertu, a HER2-directed ADC for HER2-mutated breast, ...

The safety profile in HERTHENA-Lung02 was consistent with that observed for patritumab deruxtecan in previous lung cancer trials ... discovered by Daiichi Sankyo Ltd DSNKY and being jointly ...

and being jointly developed by Daiichi Sankyo and Merck. The safety profile seen in HERTHENA-Lung02 was consistent with that observed for patritumab deruxtecan in previous lung cancer clinical trials, ...